Peptides
FOXO4-DRI
A senolytic research peptide with cell and mouse findings, including tissue-function and testicular-aging experiments; human rejuvenation has not been demonstrated.
Cell and mouse intervention evidence; no human treatment outcome in the cited studies
Also known as: FOXO4 DRI
Practical use
Evidence interpretation and clinical context
- Locate the intervention
- Check whether people received the compound or only supplied tissue samples.
- Name the actual outcome
- Keep fur, renal function, testosterone and lifespan claims separate.
- Keep species limits in the headline
- A useful summary says mouse or cell experiment before making a benefit claim.
Overview
FOXO4-DRI was designed to disrupt an interaction between FOXO4 and p53 that helps some senescent cells survive. In experimental systems, that disruption can trigger programmed cell death. DRI refers to the peptide’s altered stereochemistry and sequence design, not a clinical quality or approval designation.
Risks and limitations
Selectivity observed in laboratory models does not establish selective removal of only harmful cells in humans. Human long-term toxicity, effects on tissue repair and benefit–risk balance are not established by these experiments.
How to read this
Senescence is a cell state. A change in a senescence marker or the function of one organ should not be converted into a claim that an entire organism is younger.
Research explained
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Who was studied
Experiments in senescent cells, chemotherapy-stressed mice, a premature-aging mouse model and naturally aged mice.
What was found
The designed peptide disrupted FOXO4–p53 interaction and induced apoptosis in senescent cells. In tested mouse settings, investigators reported improvements in fitness, fur density and renal function.
What it cannot establish
These are laboratory and mouse outcomes. The report does not establish human lifespan extension, whole-body rejuvenation or a safe human intervention.
Read the original studyFOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
Who was studied
Human testicular tissue observations, a senescent mouse Leydig-cell model and treatment experiments in naturally aged mice.
What was found
The investigators found changes in senescent-cell signaling and improved testosterone-related findings after treating aged mice.
What it cannot establish
The human tissue component was observational; people were not treated. It therefore cannot establish treatment of low testosterone in men.
Read the original studyResearch status
The intervention evidence reviewed here is preclinical. Neither publication establishes a human therapeutic approval, and a research-product listing should not be interpreted as one.
Supporting sourceHuman tissue is not a human trial
Finding FOXO4 patterns in donated human tissue helps formulate a mechanism. It is different from randomly assigning people to treatment and measuring benefit and harm.
Supporting sourceClaims versus findings
Not supported
Human tissue findings prove FOXO4-DRI restores testosterone in men.
The treatment experiments in that report used cells and aged mice; the human component did not test administration.
Check the evidenceCommon questions
Do better fur or kidney measurements prove longer life?
No. Those measures describe selected functions, not a demonstrated human lifespan effect.
SourceSources
Sources checked 2026-10-01.
General education; not a personal treatment plan.